

NEW YORK, Nov. 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

[PharmaPoint: Type 2 Diabetes - Current and Future Players](#)

http://www.reportlinker.com/p01889423/PharmaPoint-Type-2-Diabetes---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Type 2 Diabetes - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Type 2 Diabetes - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Type 2 Diabetes Market. The report identifies and analyses the key companies shaping and driving the global Type 2 Diabetes market. The report provides insight into the competitive Type 2 Diabetes landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for Type 2 Diabetes - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the Type 2 Diabetes sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the Type 2 Diabetes Market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global Type 2 Diabetes market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 71.1 List of Tables 91.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 123 Market Outlook 153.1 Global Markets 153.1.1 Forecast 153.1.2 Drivers and Barriers - Global Issues 214 Current and Future Players 234.1 Overview 234.2 Trends in Corporate Strategy 264.3 Company Profiles 274.3.1 Eli Lilly 274.3.2 Bristol-Myers Squibb 304.3.3 Novo Nordisk 334.3.4 Sanofi 364.3.5 GlaxoSmithKline 394.3.6 AstraZeneca 414.3.7 Merck & Co 434.3.8 Boehringer Ingelheim 454.3.9 Takeda 474.3.10 Roche 494.3.11 Pfizer 51
4.3.12 Johnson & Johnson 535 Appendix 555.1 Bibliography 555.2 Abbreviations 575.3 Methodology 605.4 Forecasting Methodology 605.4.1 Diagnosed Type 2 Patients 605.4.2 Percent Drug-Treated Patients 615.4.3 Drugs Included in Each Therapeutic Class 615.4.4 Launch and Patent Expiry Dates 625.4.5 General Pricing Assumptions 635.4.6 Individual Drug Assumptions 645.4.7 Generic Erosion 735.4.8 Pricing of Pipeline Agents 735.5 Physicians and Specialists Included in this Study 755.6 About the Authors 775.6.1 Analyst II - CVMD 775.6.2 Therapy Director - CVMD and Infectious Disease 775.6.3 Global Head of Healthcare 785.7 About GlobalData 795.8 Disclaimer 79

List of Tables

Table 1: Global Sales Forecasts (\$m) for Type 2 Diabetes, 2012-2022 18
Table 2: Type 2 Diabetes Market - Drivers and Barriers, 2012 21
Table 3: Key Companies in the Type 2 Diabetes Market, 2012 24
Table 4: Other Companies in the Type 2 Diabetes Market, 2012 25
Table 5: Eli Lilly's Type 2 Diabetes Portfolio Assessment, 2013 29
Table 6: Eli Lilly SWOT Analysis, 2012 30
Table 7: Bristol-Myers Squibb's Type 2 Diabetes Portfolio Assessment, 2013 32
Table 8: Bristol-Myers Squibb SWOT Analysis, 2012 33
Table 9: Novo Nordisk's Type 2 Diabetes Portfolio Assessment, 2013 35
Table 10: Novo Nordisk SWOT Analysis, 2012 36
Table 11: Sanofi's Type 2 Diabetes Portfolio Assessment, 2013 38
Table 12: Sanofi SWOT Analysis, 2012 38
Table 13: GSK's Type 2 Diabetes Portfolio Assessment, 2013 40
Table 14: GSK SWOT Analysis, 2012 40
Table 15: AstraZeneca's Type 2 Diabetes Portfolio Assessment, 2013 42
Table 16: AstraZeneca SWOT Analysis, 2012 42
Table 17: Merck's Type 2 Diabetes Portfolio Assessment, 2013 44
Table 18: Merck SWOT Analysis, 2012 44
Table 19: Boehringer Ingelheim's Type 2 Diabetes Portfolio Assessment, 2013 46
Table 20: Boehringer Ingelheim SWOT Analysis, 2012 46
Table 21: Takeda's Type 2 Diabetes Portfolio Assessment, 2013 48
Table 22: Takeda SWOT Analysis, 2012 49
Table 23: Roche's Type 2 Diabetes Portfolio Assessment, 2013 50
Table 24: Roche SWOT Analysis, 2012 50
Table 25: Pfizer's Type 2 Diabetes Portfolio Assessment, 2013 52
Table 26: Pfizer SWOT Analysis, 2012 52
Table 27: J&J's Type 2 Diabetes Portfolio Assessment, 2013 53
Table 28: J&J SWOT Analysis, 2012 54
Table 29: Key Launch Dates 62
Table 30: Key Patent Expiries 62
Table 31: Number of High-Prescribing Physicians Surveyed 76

List of Figures

Figure 1: Global Sales for Type 2 Diabetes by Region, 2011-2022 20
Figure 2: Company Portfolio Gap Analysis in Type 2 Diabetes, 2012-2022 25

Companies Mentioned

Eli Lilly
Bristol-Myers Squibb
Novo Nordisk
Sanofi
GlaxoSmithKline
AstraZeneca
Merck & Co
Boehringer Ingelheim
Takeda
Roche
Pfizer
Johnson & Johnson

To order this report: [PharmaPoint: Type 2 Diabetes - Current and Future Players](http://www.reportlinker.com/p01889423/PharmaPoint-Type-2-Diabetes---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology) http://www.reportlinker.com/p01889423/PharmaPoint-Type-2-Diabetes---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Type 2 Diabetes - Current and Future Players

Written by Australian Business

Contact Clare: clare@reportlinker.com US:
(339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

RELATED LINKS <http://www.reportlinker.com>